LONDON, UK - Media OutReach Newswire - 5 June 2025 - Takeda, a global value-based, R&D-driven biopharmaceutical company, has been proudly recognized as one of the Top 10 Best Places to Work in the ...

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized by the European Commission on June 3, 2025, for newly diagnosed adult ...

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

View today's Takeda Pharmaceutical Co., Ltd. stock price and latest 4502 news and analysis. Create real-time notifications to follow any changes in the live stock price.

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Takeda manages the development costs of the ADC in Japan. Credit: Veroniksha/Shutterstock. The European Commission (EC) has approved Takeda’s antibody-drug conjugate (ADC) Adcetris (brentuximab ...